^
Association details:
Biomarker:No biomarker
Cancer:Nasopharyngeal Carcinoma
Drug Class:PD1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline

Published date:
12/15/2022
Excerpt:
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers....Recommendation 4.1….Toripalimab, camrelizumab, or tislelizumab, with gemcitabine and cisplatin, should be offered as first-line treatment for patients with recurrent or metastatic nasopharyngeal cancer
Secondary therapy:
cisplatin + gemcitabine
DOI:
10.1200/JCO.22.02328